Form 4: Vaxcyte COO Jim Wassil Sells Shares Under 10b5-1 Trading Plan

Vaxcyte's Chief Operating Officer, Jim Wassil, executed multiple sales of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc., reported the sale of common stock on July 1, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 23, 2023.
• A total of 2,990 shares were sold in multiple transactions at weighted-average prices of $75.7548, $76.7086, and $77.215.
• Following the reported transactions, Wassil beneficially owns 210,503 shares of Vaxcyte common stock.
• Wassil has granted power of attorney to several individuals at Vaxcyte and Skadden, Arps, Slate, Meagher & Flom LLP to execute and file SEC forms on his behalf.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock sales by an executive under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, regardless of the reason for the sale.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to allow insiders to sell shares while avoiding accusations of trading on non-public information.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, depending on how the market interprets the transactions.

Key Dates